Figure 3. Meta-analysis of virologic response rates for treatment-experienced patients under (a) intention-to-treat analysis (heterogeneity: I² = 88.4% and p < 0.001; publication bias: p = 0.086); and (b) pre-protocol analysis (heterogeneity: I² = 85.1% and p < 0.001; publication bias: p = 0.089).